全球药物基因组学市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

药物基因组学市场分析

药物基因组学市场正在经历显著增长，这得益于个性化医疗的进步以及人们越来越认识到遗传学在药物疗效和安全性中的作用。该领域的最新发展包括新一代测序 (NGS) 技术和生物信息学工具的整合，这增强了分析影响药物反应的遗传变异的能力。例如，Oxford Nanopore Technologies 等公司正在推出创新计划，将其测序平台与其他基因组技术相结合，从而促进制定量身定制的治疗计划。此外，尼克劳斯儿童医院等医疗机构正在采用药物基因组学技术来创建个性化疗法，最大限度地减少药物不良反应并优化治疗结果。制药公司和生物技术公司之间的合作日益增多，进一步推动了市场的发展，因为这些合作旨在开发新的药物基因组学测试和应用。监管机构也通过促进在临床环境中使用基因检测来支持这一增长，确保更安全、更有效的药物选择。总体而言，药物基因组学市场有望继续扩张，持续的创新将提高医疗保健服务的精准度。

药物基因组学市场规模

2023 年全球药物基因组学市场规模价值 86.9 亿美元，预计到 2031 年将达到 197.4 亿美元，2024 年至 2031 年预测期内的复合年增长率为 10.80%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

药物基因组学市场趋势

“新一代测序 (NGS) 技术的应用日益广泛”

The pharmacogenomics market is experiencing significant growth, driven by advancements in personalized medicine and the increasing recognition of the role genetics play in drug efficacy and safety. One notable trend in the pharmacogenomics market is the increasing adoption of next-generation sequencing (NGS) technologies to enhance personalized medicine. NGS allows for the rapid and comprehensive analysis of genetic variations that influence drug metabolism and efficacy, enabling healthcare providers to tailor treatments to individual patients based on their genetic profiles. For instance, companies such as Illumina are at the forefront of this trend, offering advanced sequencing platforms that facilitate the identification of genetic markers associated with various diseases. As more healthcare institutions recognize the value of NGS in pharmacogenomics, the demand for genetic testing is expected to surge. This trend is further supported by growing collaborations between pharmaceutical companies and diagnostic firms, aimed at developing targeted therapies that minimize adverse drug reactions and improve patient outcomes. By integrating NGS into clinical practice, the pharmacogenomics market is paving the way for a more personalized approach to medication management, ultimately enhancing the effectiveness of treatments while reducing costs associated with trial-and-error prescribing.

Report Scope and Pharmacogenomics Market Segmentation

Pharmacogenomics Market Definition

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. It combines pharmacology (the study of drugs) and genomics (the study of genes and their functions) to understand how genetic variations affect drug metabolism, efficacy, and safety. By analyzing a person's genetic profile, pharmacogenomics aims to tailor drug therapies to optimize treatment outcomes, minimize adverse effects, and improve overall healthcare by ensuring that patients receive the most appropriate medications based on their unique genetic characteristics.

Pharmacogenomics Market Dynamics

Drivers

• Rising Incidence of Adverse Drug Reactions (ADRs)

The rising incidence of adverse drug reactions (ADRs) has become a significant concern in healthcare, prompting increased awareness and demand for pharmacogenomic testing. According to the World Health Organization, ADRs account for 5–10% of hospital admissions and can lead to extended hospital stays, increased healthcare costs, and even fatalities. A study published in the Journal of the American Medical Association highlighted that around 2 million serious ADRs occur annually in the U.S., with nearly 100,000 resulting in death. This alarming trend underscores the importance of understanding the genetic variations that influence drug metabolism and response. Pharmacogenomic testing enables healthcare providers to identify patients at risk for ADRs by analyzing specific genetic markers, allowing for more tailored medication choices. For instance, individuals with variations in the CYP2D6 gene may metabolize certain medications, such as antidepressants and opioids, differently, increasing their risk of experiencing severe side effects. By integrating pharmacogenomic insights into clinical practice, healthcare professionals can significantly minimize the risks associated with ADRs, improve patient safety, and enhance treatment efficacy, ultimately driving the market growth.

• Growing Prevalence of Various Disorders

The growing prevalence of various disorders is a significant driver for the pharmacogenomics market, as it underscores the need for personalized medicine tailored to individual patient profiles. According to the World Health Organization (WHO), chronic diseases such as cancer, diabetes, and cardiovascular diseases are on the rise, accounting for over 70% of global deaths annually. For instance, the American Cancer Society estimates that in 2023, about 1.9 million new cancer cases will be diagnosed in the United States alone, highlighting an urgent need for effective treatment options that consider genetic factors influencing drug efficacy and safety. Similarly, the prevalence of diabetes has surged, with the International Diabetes Federation reporting that approximately 537 million adults are living with the condition worldwide, a number projected to rise to 783 million by 2045. Such increasing burden of disorders amplifies the demand for pharmacogenomic testing, as it enables healthcare providers to better understand how genetic variations affect individual responses to medications. By leveraging pharmacogenomic insights, clinicians can optimize treatment plans, reduce trial-and-error prescribing, ultimately driving the market growth.

Opportunities

• Increasing Supportive Government Policies

Supportive government policies and initiatives play a crucial role in promoting the integration of pharmacogenomics into clinical practice, thereby enhancing personalized medicine. For instance, in the United States, the National Institutes of Health (NIH) has launched the All of Us Research Program, which aims to gather health data from one million participants to advance precision medicine, including pharmacogenomic research. Additionally, the Food and Drug Administration (FDA) has been actively supporting the development of pharmacogenomic tests by issuing guidelines and creating databases, such as the Table of Pharmacogenomic Biomarkers in Drug Labeling, to inform healthcare providers about genetic factors affecting drug responses. Similarly, countries such as Canada and Australia have initiated funding programs to foster research into pharmacogenomics and encourage its application in clinical settings. These government-backed initiatives provide the necessary resources for research and development create an environment conducive to collaboration among academia, industry, and healthcare providers, ultimately driving the adoption of pharmacogenomic testing and improving patient care outcomes.

• Increasing Awareness of Personalized Medicine

Increasing awareness of personalized medicine is significantly propelling the growth of the pharmacogenomics market, as more consumers seek tailored healthcare solutions that cater to their individual genetic profiles. Such heightened awareness is largely fueled by educational initiatives and successful case studies showcasing the benefits of personalized treatment plans, which can lead to better health outcomes and reduced adverse drug reactions. For instance, the use of pharmacogenomic testing in oncology has gained attention, allowing oncologists to select targeted therapies based on the genetic mutations present in a patient's tumor. Companies like Myriad Genetics have pioneered tests that identify actionable mutations, guiding healthcare providers in choosing the most effective treatments for conditions like breast and lung cancer. As patients become more informed and empowered in their healthcare decisions, the demand for pharmacogenomics services is expected to rise, prompting healthcare providers to integrate these solutions into clinical practice and further creating opportunities in the market.

Restraints/Challenges

• High Costs Associated of Testing

The high costs associated with pharmacogenomic testing present a significant barrier to its widespread adoption, impacting both patients and healthcare systems. For instance, the price of genetic tests can range from several hundred to several thousand dollars, depending on the complexity of the analysis and the number of genes assessed. In addition to the test costs, there may also be associated healthcare expenses, such as consultations with specialists and follow-up care, which can further strain patients' finances. Consequently, limited access to these essential services affects individual patient care and also impede the overall advancement of personalized medicine within healthcare systems, ultimately hampering the overall market growth.

• Data Privacy Concerns

Data privacy concerns surrounding genetic testing significantly impact patient willingness to participate in pharmacogenomic studies. The collection and management of sensitive genetic information raise ethical issues related to how this data is stored, shared, and potentially misused. Many individuals fear that their genetic data could be accessed by unauthorized parties, leading to discrimination in employment or insurance based on genetic predispositions. Such apprehension can deter patients from undergoing genetic testing, even when such tests could lead to tailored and more effective treatment options. Furthermore, incidents of data breaches, such as the 2021 ransomware attack on a healthcare provider that compromised sensitive patient data, exacerbate these fears. As a result, the pharmacogenomics market faces challenges in building patient trust and ensuring robust data protection measures are in place to encourage broader participation in genetic testing initiatives.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pharmacogenomics Market Scope

The market is segmented on the basis of product and service, disease area, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Service

• Kits and Reagents
  • Sequencing Kits and Reagents
  • PCR Kits and Reagents
  • Microarray Kits and Reagents
  • 其他试剂盒和试剂
• 服务

疾病领域

• 癌症
• 心血管疾病
• 神经系统疾病
• 其他疾病领域

技术

• DNA 测序
• 微阵列
• 聚合酶链式反应
• 电泳
• 质谱分析

应用

• 药物研发
• 神经病学
• 肿瘤学
• 疼痛管理
• 其他的

最终用户

• 医院
• 研究机构
• 其他的

药物基因组学市场区域分析

对市场进行分析，并按国家、产品和服务、疾病领域、技术、应用和最终用户提供市场规模洞察和趋势，如上所述。

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在药物基因组学市场中占据领先地位，无论是市场份额还是收入，预计在整个预测期内都将保持这一主导地位。这主要归因于该地区主要行业参与者的集中，以及促进先进研发的强大医疗基础设施。此外，为了改善治疗效果，人们越来越重视早期诊断，再加上支持性报销政策，进一步增强了北美市场的增长前景。

预计亚太地区在预测期内将经历最快的增长速度，这得益于人口中胃肠道疾病发病率的上升。病例激增促使各国政府加强医疗保健计划和支持，为药物基因组学的发展创造更有利的环境。此外，对医疗保健基础设施和研究的不断增加的投资预计将加速个性化医疗的进步，进一步推动这一充满活力的地区的市场增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

药物基因组学市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的药物基因组学市场领导者是：

• 诺华公司（瑞士）
• Viatris Inc.（美国）
• Ferndale Pharma Group, Inc.（美国）
• F. Hoffmann-La Roche Ltd（瑞士）
• 辉瑞公司（美国）
• 武田药品工业株式会社 (日本)
• 阿斯利康（英国）
• 葛兰素史克公司 (英国)
• 百时美施贵宝公司 (美国)
• 礼来（美国）
• 默克公司（德国）
• 太阳制药工业有限公司 (印度)
• NATCO Pharma Limited（印度）
• 鲁冰花（印度）
• 梯瓦制药工业有限公司 (以色列)
• 勃林格殷格翰国际有限公司 (德国)
• AbbVie Inc.（美国）
• 雅培（美国）
• 拜耳公司（德国）

药物基因组学市场的最新发展

• 2024 年 5 月，Oxford Nanopore Technologies 启动了一项新的药物基因组学 (PGx) Beta 计划，旨在通过将 Twist Bioscience 的下一代测序 (NGS) 目标富集技术与 Oxford Nanopore 的测序平台相结合来推进个性化医疗
• 2024 年 2 月，南佛罗里达州尼克劳斯儿童医院实施了下一代药物基因组学技术，具体来说是 Applied Biosystems PharmacoScan 解决方案和 GeneTitan MC 快速扫描仪，为患者制定个性化治疗计划，从而最大限度地减少药物相互作用和副作用引起的并发症
• 2023 年 7 月，Illumina Inc. 与 Pillar Biosciences Inc. 建立合作伙伴关系，将 Pillar 的肿瘤学检测纳入 Illumina 的全球肿瘤学产品系列。此次合作将融合各种下一代测序解决方案，从而产生一系列出色的互补工具。测序方法的进步有望提高肿瘤学检测的效率、准确性和成本效益，最终旨在扩大患者获得个性化癌症治疗替代方案的机会
• 2023 年 4 月，Integrated DNA Technologies, Inc. 完成了对 Invitae Corporation 旗下 Archer NGS 研究检测试剂的收购，增强了 xGen NGS 产品线并加速了肿瘤学研究，特别是在识别新的癌症融合方面。此次与 IDT 广泛的 xGen NGS 产品组合的整合为研究人员提供了简化的解决方案，用于发现关键的生物标志物，尤其是与重大癌症融合相关的生物标志物
• 2023 年 1 月，QIAGEN 宣布收购 Verogen，后者是一家专门从事用于人类身份识别 (HID) 和法医应用的新一代测序 (NGS) 技术的公司

SKU-53083